Resistance trends in <i>Streptococcus pyogenes</i> (PROTEKT Years 1–3 [1999–2002])

Cohen, Robert; Green, M

doi:10.1080/1120009x.2004.11782404

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This takes different periods of time for different infectious diseases. For example, the duration of therapy for tuberculosis is months to years (Mitchison, 2005), for bacterial endocarditis several weeks (Alestig et al , 2000; Elliott et al , 2004) and for streptococcal sore throat up to 10 days (Cohen and Green, 2004). Biofilms on prosthetic implants are particularly difficult to cure.…”

Section: New Methods That Have the Potential To Deliver Novel Antibiomentioning

confidence: 99%

Novel approaches to developing new antibiotics for bacterial infections

Coates

2007

British J Pharmacology

191

131

View full text Add to dashboard Cite

Antibiotics are an essential part of modern medicine. The emergence of antibiotic‐resistant mutants among bacteria is seemingly inevitable, and results, within a few decades, in decreased efficacy and withdrawal of the antibiotic from widespread usage. The traditional answer to this problem has been to introduce new antibiotics that kill the resistant mutants. Unfortunately, after more than 50 years of success, the pharmaceutical industry is now producing too few antibiotics, particularly against Gram‐negative organisms, to replace antibiotics that are no longer effective for many types of infection. This paper reviews possible new ways to discover novel antibiotics. The genomics route has proven to be target rich, but has not led to the introduction of a marketed antibiotic as yet. Non‐culturable bacteria may be an alternative source of new antibiotics. Bacteriophages have been shown to be antibacterial in animals, and may find use in specific infectious diseases. Developing new antibiotics that target non‐multiplying bacteria is another approach that may lead to drugs that reduce the emergence of antibiotic resistance and increase patient compliance by shortening the duration of antibiotic therapy. These new discovery routes have given rise to compounds that are in preclinical development, but, with one exception, have not yet entered clinical trials. For the time being, the majority of new antibiotics that reach the marketplace are likely to be structural analogues of existing families of antibiotics or new compounds, both natural and non‐natural which are screened in a conventional way against live multiplying bacteria. British Journal of Pharmacology (2007) 152, 1147–1154; doi:; published online 20 August 2007

show abstract

Section: New Methods That Have the Potential To Deliver Novel Antibiomentioning

confidence: 99%